Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Declines By 24.5%

Gain Therapeutics, Inc. (NASDAQ:GANX) saw a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 348,800 shares, a decrease of 24.5% from the February 13th total of 462,200 shares. Based on an average trading volume of 232,700 shares, the short-interest ratio is presently 1.5 days. Currently, 1.4% of the shares of the stock are sold short.

Gain Therapeutics Stock Down 0.8 %

GANX stock opened at $2.38 on Wednesday. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $4.63. The firm has a market cap of $63.13 million, a PE ratio of -2.16 and a beta of 0.14. The firm has a 50 day simple moving average of $2.23 and a 200 day simple moving average of $2.01. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99.

Institutional Trading of Gain Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sprott Inc. purchased a new stake in shares of Gain Therapeutics in the 4th quarter valued at approximately $30,000. Benedict Financial Advisors Inc. purchased a new stake in shares of Gain Therapeutics in the 4th quarter valued at approximately $35,000. Bridgeway Capital Management LLC purchased a new stake in shares of Gain Therapeutics in the 4th quarter valued at approximately $65,000. Northern Trust Corp lifted its position in shares of Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after acquiring an additional 39,642 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Gain Therapeutics in the 4th quarter valued at approximately $198,000. 11.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on GANX. Scotiabank began coverage on shares of Gain Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target for the company. Roth Capital raised shares of Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research note on Monday. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $7.00 price target on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.